Welcome to our dedicated page for Clene news (Ticker: CLNN), a resource for investors and traders seeking the latest updates and insights on Clene stock.
Clene Inc. reports developments as a late clinical-stage biopharmaceutical company developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases. Through Clene Nanomedicine Inc., the company focuses on improving mitochondrial health and protecting neuronal function in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease.
Recurring news centers on CNM-Au8®, an investigational nanocrystal suspension designed to target mitochondrial function and the NAD pathway while reducing oxidative stress. Company updates include ALS biomarker and expanded-access data, FDA meeting and regulatory communications, operating and financial results, registered direct financing activity, shareholder communications, voting matters and investor-conference presentations.
Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company, has showcased its corporate presentation on M-Vest.com and announced participation in the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Conference from March 17-19, 2021. At the conference, Clene will present on-demand and engage in a live fireside chat on March 19 at 11:00 am ET. The company's lead drug, CNM-Au8, aims to treat neurodegenerative diseases and is currently in advanced clinical trials for ALS, multiple sclerosis, and Parkinson’s disease. For more information, visit Clene’s investor website.
Clene Inc. (NASDAQ: CLNN) announced that over 50% of participants have been enrolled in the HEALEY ALS Platform Trial, the first registration trial for amyotrophic lateral sclerosis (ALS). This trial, led by Mass General Hospital, aims to evaluate the safety and efficacy of multiple investigational products, including Clene's candidate, CNM-Au8. The study includes up to 54 expert ALS clinical trial sites across the U.S. and is supported by philanthropic funding. Full enrollment targets 160 patients, with results potentially impacting ALS treatment strategies.
Clene Inc. (NASDAQ: CLNN) announced that its subsidiary, Clene Nanomedicine, will present at key investor conferences. The H.C. Wainwright Global Life Sciences Conference will feature a pre-recorded presentation available on-demand from March 9, 2021. A Fireside Chat is scheduled for the 33rd Annual Roth Conference on March 15, 2021, at 5:30 p.m. ET. Additionally, a live corporate presentation will occur at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 4:30 p.m. ET. Webcasts will be accessible on Clene's website.
Clene Inc. (NASDAQ: CLNN) announced promising interim data from its Phase 2 study of CNM-Au8, a nanocatalyst aimed at treating Parkinson's disease (PD). The data indicate significant improvements in CNS bioenergetic metabolites among PD patients. The company was awarded a grant from The Michael J. Fox Foundation to further develop CNM-Au8, with a Phase 2 proof-of-concept trial expected to start in 2021. Findings suggest CNM-Au8 may slow PD progression by enhancing neuronal survival and reducing oxidative stress.
Clene Inc. (NASDAQ: CLNN) announced positive interim data from its studies, VISIONARY-MS and REPAIR-MS, presented at the ACTRIMS Forum 2021. Interim results demonstrate CNM-Au8's potential in improving neurological functions in multiple sclerosis (MS) patients. The VISIONARY-MS trial showed significant enhancements in MS Functional Composite (MSFC) scores compared to baseline (p0.0001). The REPAIR-MS study indicated notable metabolic improvements in CNS markers, suggesting a homeostatic effect of CNM-Au8. Unblinded topline data for both studies are expected in 2022.
Clene Inc. (NASDAQ: CLNN) will present updated interim data from its REPAIR-MS and VISIONARY-MS studies at the ACTRIMS Forum 2021, from February 25-27. The REPAIR-MS study examines the safety and efficacy of CNM-Au8 in patients diagnosed with MS, while the VISIONARY-MS trial focuses on its effects on chronic visual impairment in stable relapsing MS patients. Key endpoints of VISIONARY-MS include improvements in low contrast letter acuity and other functional tests after treatment. The results may highlight CNM-Au8’s potential in treating neurodegenerative diseases.
Clene Inc. (NASDAQ: CLNN) announced that its subsidiary Clene Nanomedicine received ANVISA approval to conduct a Phase 2 clinical study in Brazil. The trial will assess the efficacy and safety of CNM-ZnAg in treating acutely symptomatic, non-hospitalized COVID-19 patients. It aims to enroll approximately 276 patients, focusing on reducing hospitalizations at 28 days. While vaccines are available, the need for COVID-19 therapeutics persists. Results are expected in the second half of 2021, showcasing the company's dedication to advancing therapeutic solutions.
Clene Inc. (NASDAQ: CLNN) announced that its subsidiary received a Notice of Allowance from the USPTO for a patent regarding the use of its gold nanocrystals, CNM-Au8, in treating Multiple Sclerosis (MS). This patent expands Clene's intellectual property, which now includes over 130 issued and pending patents. CNM-Au8 is being tested in Phase 2 and 3 trials for MS and Amyotrophic lateral sclerosis (ALS), targeting an estimated $23 billion treatment market. Interim results from ongoing studies show potential improvements in CNS bioenergetic metabolites.
Clene Inc. (NASDAQ: CLNN) completed its merger with Tottenham Acquisition I Limited, effective December 31, 2020, providing approximately $31.9 million in funding, including $22.4 million from PIPE financing. Clene's clinical pipeline includes ongoing Phase 3 and multiple Phase 2 studies targeting neurodegenerative diseases such as ALS, MS, and Parkinson’s disease. The company aims to leverage its nanocatalysis technology for innovative treatments. Interim data from recent trials indicate promising outcomes, positioning Clene for potential growth in this high-need medical area.